TITLE Project 3: Predicting therapeutic sensitivity in cancer. ABSTRACT Somatic genetic alterations in cancer have been linked with response to targeted therapeutics and resistance to therapy. Methods that model and predict therapeutic sensitivity of cancer can be extremely useful in the development of more effective treatments. Our goal is to model, predict, and target therapeutic sensitivity and resistance of cancer. Our proposed approach is to utilize 3-dimensional (3-D) models of glioblastoma (gliomaspheres, GS) that recapitulate the nature of genetics lesions in primary tumors to experimentally validate computational Machine Learning predictions based on genomic information. Our approach in Aim 1 is to build a computational framework that incorporates genomic data, drug properties and responses, and known drug targets and network models of pathways and protein complexes to predict the therapeutic response of 80 genomically annotated GSs. Then, in Aim 2 we will experimentally validate our computational predictions of therapeutic sensitivity across the library of GSs, test combinatorial predictions, and examine the molecular mechanisms by which candidate genes alter drug responses. Single or multi-lesion sensitivity will be evaluated by RNA interference or cDNA overexpression. Finally, we will investigate the role of cell heterogeneity in the mechanism of drug resistance at the single cell level using topological methods, developed in Project 2 and in the Mathematical Core. The ultimate goal of our studies will be to uncover mechanistic insights into genotype- dependent sensitivity to drugs or synthetic lethal relationships. Ultimately, our studies will deliver key information for the development of multiple gene- and pathway-based biomarkers for personalized cancer therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54CA193313-01
Application #
8866154
Study Section
Special Emphasis Panel (ZCA1-TCRB-5 (J1))
Project Start
2015-05-19
Project End
2020-04-30
Budget Start
2015-05-19
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$403,256
Indirect Cost
$151,221
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Frattini, VĂ©ronique; Pagnotta, Stefano M; Tala et al. (2018) A metabolic function of FGFR3-TACC3 gene fusions in cancer. Nature 553:222-227
Gartrell, Robyn D; Marks, Douglas K; Hart, Thomas D et al. (2018) Quantitative Analysis of Immune Infiltrates in Primary Melanoma. Cancer Immunol Res 6:481-493
Giudice, I Del; Rigolin, G M; Raponi, S et al. (2018) Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia 32:543-546
Rabadan, Raul; Bhanot, Gyan; Marsilio, Sonia et al. (2018) On statistical modeling of sequencing noise in high depth data to assess tumor evolution. J Stat Phys 172:143-155
Levitin, Hanna Mendes; Yuan, Jinzhou; Sims, Peter A (2018) Single-Cell Transcriptomic Analysis of Tumor Heterogeneity. Trends Cancer 4:264-268
Arnes, Luis; Liu, Zhaoqi; Wang, Jiguang et al. (2018) Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. Gut :
Cimino, Patrick J; Kim, Youngmi; Wu, Hua-Jun et al. (2018) Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev 32:512-523
Puchalski, Ralph B; Shah, Nameeta; Miller, Jeremy et al. (2018) An anatomic transcriptional atlas of human glioblastoma. Science 360:660-663
Lee, Suk Hyung; Hu, Wenhuo; Matulay, Justin T et al. (2018) Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell 173:515-528.e17
Yuan, Jinzhou; Levitin, Hanna Mendes; Frattini, Veronique et al. (2018) Single-cell transcriptome analysis of lineage diversity in high-grade glioma. Genome Med 10:57

Showing the most recent 10 out of 35 publications